<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05092360</url>
  </required_header>
  <id_info>
    <org_study_id>ALKS 4230-007</org_study_id>
    <secondary_id>GOG-3063</secondary_id>
    <secondary_id>ENGOT-OV68</secondary_id>
    <secondary_id>KEYNOTE-C71</secondary_id>
    <nct_id>NCT05092360</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab</brief_title>
  <acronym>ARTISTRY-7</acronym>
  <official_title>A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination&#xD;
      with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients&#xD;
      with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be centrally allocated in a randomized fashion (3:1:1:3) to receive either:&#xD;
&#xD;
      Arm 1: Nemvaleukin and pembrolizumab combination therapy Arm 2: Pembrolizumab monotherapy Arm&#xD;
      3: Nemvaleukin monotherapy Arm 4: Investigator's choice chemotherapy include one of the&#xD;
      following: pegylated liposomal doxorubicin (PLD), paclitaxel, topotecan, or gemcitabine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) as assessed by Investigator</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate as assessed by Investigator</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) as assessed by Investigator</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) as assessed by Investigator</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) as assessed by Investigator</measure>
    <time_frame>Up to 18-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer antigen (CA)-125 response as defined by the Gynecologic Cancer InterGroup (GCIG)</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">376</enrollment>
  <condition>Platinum-resistant Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>Nemvaleukin and Pembrolizumab Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nemvaleukin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigator's Choice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Options for protocol-specific Investigator's choice chemotherapy include one of the following: pegylated liposomal doxorubicin (PLD), paclitaxel, topotecan, or gemcitabine. The Investigator will pre-select the Investigator's choice treatment before the randomization of each patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nemvaleukin and Pembrolizumab Combination</intervention_name>
    <description>Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes and Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes</description>
    <arm_group_label>Nemvaleukin and Pembrolizumab Combination</arm_group_label>
    <other_name>Nemvaleukin alfa</other_name>
    <other_name>ALKS 4230</other_name>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nemvaleukin</intervention_name>
    <description>Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes</description>
    <arm_group_label>Nemvaleukin</arm_group_label>
    <other_name>Nemvaleukin alfa</other_name>
    <other_name>ALKS 4230</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Liposomal Doxorubicin (PLD)</intervention_name>
    <description>40 mg/m2; Day 1 of 28-day cycles; IV infusion; 1 mg/min (Cycle 1); 60 min infusion (Cycles 2+)</description>
    <arm_group_label>Investigator's Choice</arm_group_label>
    <other_name>PLD- CAELYX</other_name>
    <other_name>DOXIL</other_name>
    <other_name>LIPODOX</other_name>
    <other_name>Myocet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>80 mg/m2; Days 1, 8, 15, and 22 of 28-day cycles; IV infusion over 60 min</description>
    <arm_group_label>Investigator's Choice</arm_group_label>
    <other_name>Nov-Onxol</other_name>
    <other_name>Taxol</other_name>
    <other_name>Onxol</other_name>
    <other_name>Paclitaxel Novaplus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>4 mg/m2; Days 1, 8, and 15 of 28-day cycles; or 1.25 mg/m2, Days 1 through 5 of 21-day cycles; IV infusion over 30 min</description>
    <arm_group_label>Investigator's Choice</arm_group_label>
    <other_name>Hycamtin</other_name>
    <other_name>Potactasol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1,000 mg/m2; Days 1 and 8 of 21-day cycles; IV infusion over 30 min</description>
    <arm_group_label>Investigator's Choice</arm_group_label>
    <other_name>Gemzar</other_name>
    <other_name>Infugem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is female and ≥18 years of age.&#xD;
&#xD;
          -  Patient has histologically confirmed diagnosis of EOC (ie, high-grade serous,&#xD;
             endometrioid of any grade, clear cell), fallopian tube cancer, or primary peritoneal&#xD;
             cancer.&#xD;
&#xD;
          -  Patient has platinum-resistant/refractory disease, defined as disease progression&#xD;
             within 180 days following the last administered dose of platinum therapy beyond&#xD;
             first-line setting (resistant) or lack of response or disease progression while&#xD;
             receiving the most recent platinum-based therapy (refractory). Patient must have&#xD;
             progressed radiographically on or after their most recent line of anticancer therapy.&#xD;
&#xD;
          -  Patient must have received at least 1 prior line of systemic anticancer therapy in the&#xD;
             platinum sensitive setting, and no more than 5 prior lines of systemic anticancer&#xD;
             therapy in the platinum-resistant setting. Patient must have received at least 1 line&#xD;
             of therapy containing bevacizumab.&#xD;
&#xD;
          -  Patient has at least one measurable lesion that qualifies as a target lesion based on&#xD;
             RECISTv1.1.&#xD;
&#xD;
          -  Patient is willing to undergo a pre-treatment tumor biopsy or provide qualifying&#xD;
             archival tumor tissue.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has primary platinum-refractory disease or primary platinum resistance,&#xD;
             defined as disease progression during first-line platinum-based therapy (refractory)&#xD;
             or disease progression &lt;3 months after completion of first-line platinum-based therapy&#xD;
             (resistant).&#xD;
&#xD;
          -  Patient has histologically confirmed diagnosis of EOC with mucinous or carcinosarcoma&#xD;
             subtype.&#xD;
&#xD;
          -  Patient has nonepithelial tumor (eg, germline or stromal cell tumor) or ovarian tumor&#xD;
             with low malignant potential (ie, borderline or low-grade serous tumor).&#xD;
&#xD;
          -  Patient requires fluid drainage (eg, paracentesis, thoracentesis, pericardiocentesis)&#xD;
             of ≥500 mL within 6 weeks of first dose of study drug.&#xD;
&#xD;
          -  Patient has received prior IL-2-based or IL-15-based cytokine therapy; patient has had&#xD;
             exposure, including intralesional, to IL-12 or analogs thereof.&#xD;
&#xD;
          -  Patient has prior exposure to any anti-PD1/PD-L1 therapy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rita Dalal, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Senior Direct, Global Clinical Services</last_name>
    <phone>888-235-8008 (US Only)</phone>
    <email>clinicaltrials@alkermes.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Senior Direct, Global Clinical Services</last_name>
    <phone>1-571-599-2702 (Global)</phone>
    <email>clinicaltrials@alkermes.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PROC</keyword>
  <keyword>EOC</keyword>
  <keyword>ALKS 4230</keyword>
  <keyword>IL-2</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>KEYNOTE-C71</keyword>
  <keyword>Platinum Resistant</keyword>
  <keyword>Epithelian Ovarian Cancer</keyword>
  <keyword>Nemvaleukin alfa</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>ARTISTRY-7</keyword>
  <keyword>ART-7</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>pegylated liposoma doxorubicin</keyword>
  <keyword>PLD</keyword>
  <keyword>topotecan</keyword>
  <keyword>gemzar</keyword>
  <keyword>gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

